Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer

British Journal of Cancer

Volumn 79, Issue 5-6, 1999, Pages 888-894

  Foekens, J A ^a,d   Diamandis, E P ^a   Yu, H ^b   Look, M P ^a   Meijer van Gelder, M E ^a   Van Putten, W L J ^c   Klijn, J G M ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b Diagnostic Systems Laboratories Inc   (United States)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Breast cancer prognosis; Prostate specific antigen; Response to therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID RECEPTOR; TAMOXIFEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CYTOSOL; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; PROSTATE-SPECIFIC ANTIGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS;

EID: 0033003104     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690142     Document Type: Article

References (51)

1. Andreasen PA, Kjøller L, Christensen L and Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
2. Barlow RE, Bartelomew DJ, Bremmer JM and Brunck HD (1972) Statistical Interference Under Order Restrictions. John Wiley & Sons: London
3. Blat C, Villaudy J and Binoux M (1994) In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 93: 2226-2230
4. Campbell PG, Novak JF, Yanosick TB and McMaster JH (1992) Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 130: 1401-1412
5. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA and Andriole GL (1991) Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161
6. Cohen P, Graves HCB, Peehl DM, Kamarci M, Giundice LC and Rosenfeld RG (1992) Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053
7. Cohen P, Peehl DM, Graves HCB and Rosenfeld RG (1994) Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142: 407-415
8. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME and Rosen N (1990) Insulin-like growth factor receptor expression and function in human breast cancer cells. Cancer Res 50: 48-53
9. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen PI, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266
10. Diamandis ER (1996) Prostate specific antigen - new applications in breast and other cancers. Anticancer Res 16: 3983-3986
11. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618
12. Duffy MJ, O'Grady P, Devaney D, O'Siorian L, Fennelly JJ and Lijnen HJ (1988) Urokinase plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer 62: 531-533
13. EORTC Breast Cancer Cooperative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16: 1513-1515
14. Ferguson RA, Yu H, Kalyvas M, Zammit S and Diamandis EP (1996) Ultrasensitive detection of prostate specific antigen by a new time resolved immunofluorometric assay and the Immulite immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. Clin Chem 42: 675-684
15. Figueroa JA and Yee D (1992) The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer. Breast Cancer Res Treat 22: 81-90
16. Foekens JA, Portengen H, van Putten WLJ, Peters HA, Krijnen HLJM, Alexieva-Figusch J and Klijn JGM (1989) Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 49: 5823-5828
17. Foekens JA, Schmitt M, van Pulten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
18. Foekens JA, Portengen H, Look MP, van Pullen WLJ, Thirion B, Bontenbal M and Klijn JGM (1994) Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 70: 1217-1223
19. Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H and Klijn JGM (1995) Urokinase-type plasminogen activator and its inhibitor PA1-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756
20. Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA and Diamandis EP (1995) Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 72: 728-731
21. Jänicke F, Schmitt M, Hafter R, Hollreider A, Babie R, Ulm K, Gössner W and Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
22. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B and Karasik A (1993) Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77: 229-233
23. Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
24. Lahti EI, Knip M and Laatikainen TJ (1994) Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 74: 618-624
25. Lai LC, Erbas H, Lennard TW and Peaston RT (1996) Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer 66: 743-746
26. Lalou C, Silve C, Rosato R, Segivia B and Binoux M (1994) Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology 135: 2318-2326
27. Lehrer S, Terk M, Picolli SP, Song HK, Lavagnini P and Luderer AA (1996) Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. Br J Cancer 74: 871-873
28. Levesque M, Hu H, D'Costa M and Diamandis EP (1995a) Prostate-specific antigen expression by various tumors. J Clin Lab Anal 9: 123-128
29. Levesque MA, Clark GM, Yu H and Diamandis EP (1995b) Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. Br J Cancer 72: 720-727
30. Lilja II (1985) A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76: 1899-1903
31. Lonning PE, Hall K, Aakvaag A and Lien EA (1992) Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 52: 4719-4723
32. Manni A, Badger B, Wei L, Zaenglein A, Grove R, Khin S, Heitjan D, Shimasaki S and Ling N (1994) Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. Cancer Res 54: 2934-2942
33. Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F and Diamandis EP (1997) Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab 82: 777-780
34. Mignatti P and Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195
35. Nicholson S, Sainsbury JRC, Halerow P, Farndon JR, Chambers P and Harris AL (1989) Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i: 182-185
36. Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923
37. Osborne CK, Coronado EB, Kitten LJ, Arteaga CL, Fuqua SAW, Ramasharma K, Marschal M and Li CH (1989) Insulin-like growth factor-II: a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-1 receptor. Mol Endocrinol 3: 1701-1709
38. Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, Fisher B and Margolese R (1990) Effect of tamoxifen on serum insulin-like growth factor 1 levels in stage 1 breast cancer patients. J Natl Cancer Inst 82: 1693-1697
39. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B and Osborne CK (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284-1291
40. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F and Graeff H (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemostasis 78: 285-296
41. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS and Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916
42. Van Putten WLJ, Klijn JGM, Meijer-van Gelder ME, Look MP and Foekens JA (1996) Multiparameter analysis of prognostic factors in breast cancer. In Breast Cancer Advances in Biology and Therapeutics. Calvo F, Crepin M and Magdelenat H (eds.), pp. 209-215. John Libbey Eurotext: Montrouge
43. Yee D, Sharma J and Hilsenbeck SG (1994) Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst 86: 1785-1789
44. Yu H, Diamandis EP and Sutherland DJA (1994a) Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 27: 75-79
45. Yu H, Diamandis ER, Zarghami N and Gras L (1994b) Induction of prostate-specific antigen production by steroids and tamoxifen in breast cancer cells lines. Breast Cancer Res Treat 32: 291-300
46. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R and Sismondi P (1995a) Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104-2110
47. Yu H, Diamandis EP, Levesque M, Asa SL, Monne M and Croce CM (1995b) Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res 55: 1603-1606
48. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M and Croce CM (1996a) Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40: 171-178
49. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM and Diamandis EP (1996b) Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer 74: 1242-1247
50. Yu H, Levesque A, Clark GM and Diamandis EP (1998) Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 4: 1489-1497
51. Zarghami N, Grass L and Diamandis EP (1997) Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 75: 579-588